Search hospitals > California > Torrance
Harbor-UCLA Medical Center
Claim this profileTorrance, California 90502
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in High Blood Pressure
Conducts research for Pulmonary Hypertension
Conducts research for Pulmonary Arterial Hypertension
Conducts research for Infections
227 reported clinical trials
9 medical researchers
Summary
Harbor-UCLA Medical Center is a medical facility located in Torrance, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Infections and other specialties. Harbor-UCLA Medical Center is involved with conducting 227 clinical trials across 283 conditions. There are 9 research doctors associated with this hospital, such as William French, MD, Loren G Miller, Sarah Tomassetti, and Mark Archie, MD.Top PIs
William French, MDLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center4 years of reported clinical research
Studies Obesity
Studies Diabetes
5 reported clinical trials
6 drugs studied
Loren G MillerLundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center4 years of reported clinical research
Studies Infections
Studies Contagious Diseases
4 reported clinical trials
6 drugs studied
Sarah TomassettiLundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 840373 years of reported clinical research
Studies Hemolysis
Studies Thrombocytopenic Purpura
5 reported clinical trials
8 drugs studied
Mark Archie, MDHarbor-UCLA Medical Center4 years of reported clinical research
Studies Arterial Occlusive Disease
Studies Peripheral Arterial Disease
3 reported clinical trials
3 drugs studied
Clinical Trials running at Harbor-UCLA Medical Center
Stroke
Ischemic Stroke
Multiple Sclerosis
Infections
Contagious Diseases
Vasculitis
Pulmonary Arterial Hypertension
High Blood Pressure
Cardiac Arrest
Transient Ischemic Attack
Milvexian
for Stroke
This trial is testing whether milvexian can help prevent another stroke in people who have already had one by stopping blood clots from forming. Milvexian may reduce the risk of stroke without significant bleeding.
Recruiting1 award Phase 35 criteria
Asundexian
for Stroke Prevention
This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
Recruiting1 award Phase 3
BP REACH Intervention
for High Blood Pressure
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services public healthcare system. The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are: * Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care? * Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?
Recruiting1 award N/A3 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Harbor-UCLA Medical Center?
Harbor-UCLA Medical Center is a medical facility located in Torrance, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Infections and other specialties. Harbor-UCLA Medical Center is involved with conducting 227 clinical trials across 283 conditions. There are 9 research doctors associated with this hospital, such as William French, MD, Loren G Miller, Sarah Tomassetti, and Mark Archie, MD.